Summary
Amgen Inc. (AMGN) filed an 8-K on October 24, 2011, primarily to announce its unaudited financial results for the third quarter and the first nine months of 2011, along with its financial position as of September 30, 2011. The filing highlights the company's use of non-GAAP financial measures to provide supplemental information to investors, aiming to facilitate analysis by excluding certain non-recurring or non-cash items. Key adjustments to GAAP measures include impacts from stock option expensing, depreciation charges related to the Boehringer Ingelheim (BI) Fremont facility transaction, amortization of acquired R&D technology and product rights, cost-saving initiatives leading to expense reversals and severance costs, merger-related expenses, contingent consideration adjustments from the BioVex acquisition, legal expenses, and non-cash interest expense on convertible notes. The company believes these adjustments offer a clearer view of ongoing operational performance and comparability across periods.
Key Highlights
- 1Amgen reported its unaudited financial results for the three and nine months ended September 30, 2011.
- 2The company provided its unaudited financial position as of September 30, 2011.
- 3Amgen utilized non-GAAP financial measures, excluding specific items to provide supplemental investor insights.
- 4Key non-GAAP adjustments include the impact of stock option expensing, depreciation related to the BI Fremont transaction, and amortization of acquired intangible assets.
- 5Other significant adjustments involve cost-saving initiatives, merger-related expenses, and contingent consideration from acquisitions like BioVex.
- 6The filing also noted non-cash interest expense on convertible notes and certain legal expenses as items excluded from non-GAAP measures.
- 7Amgen believes these non-GAAP measures aid in comparing performance across different periods, especially concerning the impact of acquisitions and cost efficiencies.